Latirab DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed to manage gastrointestinal disorders characterized by acid-related symptoms and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric emptying and alleviates nausea and vomiting by enhancing upper gastrointestinal motility without crossing the blood-brain barrier significantly, thereby minimizing central nervous system side effects. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The synergistic action of these agents in Latirab DSR Capsule offers comprehensive management of symptoms including heartburn, regurgitation, bloating, and delayed gastric emptying. This combination is particularly beneficial in patients requiring both acid suppression and prokinetic effects. Latirab DSR Capsule should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to components, and caution in patients with cardiac arrhythmias or hepatic impairment. Regular monitoring and adherence to recommended dosage enhance therapeutic outcomes and safety.